[go: up one dir, main page]

NO20030858L - Metode for behandling av en BCL-2-lidelse med BCL-2-antisens- oligomerer - Google Patents

Metode for behandling av en BCL-2-lidelse med BCL-2-antisens- oligomerer

Info

Publication number
NO20030858L
NO20030858L NO20030858A NO20030858A NO20030858L NO 20030858 L NO20030858 L NO 20030858L NO 20030858 A NO20030858 A NO 20030858A NO 20030858 A NO20030858 A NO 20030858A NO 20030858 L NO20030858 L NO 20030858L
Authority
NO
Norway
Prior art keywords
bcl
disorder
treating
antisense oligomers
antisense
Prior art date
Application number
NO20030858A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030858D0 (no
Inventor
Jr Raymond P Warrell
Robert E Klem
Howard Fingert
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27397795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030858(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genta Inc filed Critical Genta Inc
Publication of NO20030858D0 publication Critical patent/NO20030858D0/no
Publication of NO20030858L publication Critical patent/NO20030858L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20030858A 2000-08-25 2003-02-24 Metode for behandling av en BCL-2-lidelse med BCL-2-antisens- oligomerer NO20030858L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22797000P 2000-08-25 2000-08-25
US23700900P 2000-09-29 2000-09-29
US09/709,170 US7795232B1 (en) 2000-08-25 2000-11-10 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PCT/US2001/026414 WO2002017852A2 (fr) 2000-08-25 2001-08-23 Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2

Publications (2)

Publication Number Publication Date
NO20030858D0 NO20030858D0 (no) 2003-02-24
NO20030858L true NO20030858L (no) 2003-04-24

Family

ID=27397795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030858A NO20030858L (no) 2000-08-25 2003-02-24 Metode for behandling av en BCL-2-lidelse med BCL-2-antisens- oligomerer

Country Status (32)

Country Link
US (2) US7795232B1 (fr)
EP (2) EP1313514B1 (fr)
JP (1) JP2004507480A (fr)
KR (1) KR20030034153A (fr)
CN (1) CN1471408A (fr)
AP (1) AP2003002761A0 (fr)
AT (1) ATE432717T1 (fr)
AU (2) AU8837301A (fr)
BG (1) BG107641A (fr)
BR (1) BR0113447A (fr)
CA (1) CA2419480A1 (fr)
CY (1) CY1109340T1 (fr)
CZ (1) CZ301582B6 (fr)
DE (1) DE60138892D1 (fr)
DK (1) DK1313514T3 (fr)
DZ (1) DZ3471A1 (fr)
EA (1) EA005424B1 (fr)
EE (1) EE200300074A (fr)
ES (1) ES2327904T3 (fr)
GE (1) GEP20063934B (fr)
HR (1) HRP20030102A2 (fr)
HU (1) HUP0303125A2 (fr)
IL (1) IL154409A0 (fr)
MX (1) MXPA03001575A (fr)
NO (1) NO20030858L (fr)
OA (1) OA12586A (fr)
PL (1) PL363050A1 (fr)
PT (1) PT1313514E (fr)
SK (1) SK3652003A3 (fr)
UA (1) UA77945C2 (fr)
WO (1) WO2002017852A2 (fr)
YU (1) YU13603A (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
EP2261368A1 (fr) 2002-03-13 2010-12-15 Genomic Health, Inc. Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
AU2003295561A1 (en) * 2002-11-14 2004-06-15 Genta Salus Llc Inhibitory oliogonucleotides targeted to bcl-2
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
DE10258677A1 (de) * 2002-12-13 2004-06-24 Elez, Vera, Dr. Kombinations-antisense-Oligonukleotid-Krebstherapie
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1597391B1 (fr) 2003-02-20 2008-10-29 Genomic Health, Inc. Utilisation d'arn intronique pour mesurer l'expression genique
EP1640452A4 (fr) 2003-05-30 2009-12-23 Nippon Shinyaku Co Ltd Arn oligobicatenaire inhibant l'expression de bcl-2 et composition medicinale contenant cet arn
WO2005039382A2 (fr) 2003-06-24 2005-05-06 Genomic Health Prediction de probabilite de la recurrence d'un cancer
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
ATE498022T1 (de) 2003-12-23 2011-02-15 Genomic Health Inc Universelle vervielfältigung von fragmentierter rns
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
EP2163650B1 (fr) 2004-04-09 2015-08-05 Genomic Health, Inc. Marqueurs d'expression de gènes pour prédire une réponse à la chimiothérapie
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
CA2577938C (fr) 2004-08-26 2013-04-16 Himanshu Brahmbhatt Administration d'acides nucleiques fonctionnels dans des cellules de mammiferes via de minicellules intactes derivees par bacteries
AU2013203202B2 (en) * 2004-08-26 2017-02-16 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells
AU2005304878B2 (en) 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (ja) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
ES2419106T3 (es) 2005-12-01 2013-08-19 Pronai Therapeutics, Inc. Formulación de liposomas anfóteros
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN100368424C (zh) * 2006-07-21 2008-02-13 福建金山生物制药股份有限公司 抑制肿瘤的反义核苷酸
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
DE102007020554A1 (de) * 2007-04-27 2008-10-30 Henkel Ag & Co. Kgaa Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009071681A2 (fr) * 2007-12-07 2009-06-11 Santaris Pharma A/S Composés d'antagoniste d'arn utiles pour moduler bcl-2
AU2009316773A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
MX2012001244A (es) 2009-07-30 2012-03-26 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta.
JP5963680B2 (ja) * 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
PL3319995T3 (pl) * 2015-07-07 2019-09-30 F. Hoffmann-La Roche Ag Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
JP7707184B2 (ja) * 2020-03-18 2025-07-14 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク 修飾短干渉ｒｎａ組成物、及びがんの処置におけるそれらの使用
WO2021231486A1 (fr) * 2020-05-13 2021-11-18 Unity Biotechnology, Inc. Traitement du cancer par l'induction de sénescence suivie d'un sénolytique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
CA2025907A1 (fr) 1989-09-21 1991-03-22 Franklin D. Collins Methode pour le transport de composes a travers la barriere hemato-encephalique
EP0633934A1 (fr) 1992-04-02 1995-01-18 Imperial Cancer Research Technology Limited Cellules modifiees et procede de traitement
ATE200427T1 (de) 1992-10-21 2001-04-15 Univ Temple Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
OA12586A (en) 2006-06-07
BG107641A (bg) 2004-01-30
HUP0303125A2 (hu) 2003-12-29
CA2419480A1 (fr) 2002-03-07
DZ3471A1 (fr) 2002-03-07
PL363050A1 (en) 2004-11-15
NO20030858D0 (no) 2003-02-24
EP1313514A4 (fr) 2005-07-13
EP1313514B1 (fr) 2009-06-03
AU8837301A (en) 2002-03-13
WO2002017852A2 (fr) 2002-03-07
IL154409A0 (en) 2003-09-17
EP1313514A2 (fr) 2003-05-28
AU2001288373B2 (en) 2006-05-11
ATE432717T1 (de) 2009-06-15
CN1471408A (zh) 2004-01-28
SK3652003A3 (en) 2003-08-05
JP2004507480A (ja) 2004-03-11
EA005424B1 (ru) 2005-02-24
EE200300074A (et) 2004-12-15
DK1313514T3 (da) 2009-10-12
US20100216867A1 (en) 2010-08-26
ES2327904T3 (es) 2009-11-05
EP2135623A1 (fr) 2009-12-23
BR0113447A (pt) 2003-07-08
MXPA03001575A (es) 2004-11-01
KR20030034153A (ko) 2003-05-01
AP2003002761A0 (en) 2003-06-30
WO2002017852A3 (fr) 2003-04-03
PT1313514E (pt) 2009-09-01
US7795232B1 (en) 2010-09-14
CY1109340T1 (el) 2014-07-02
CZ301582B6 (cs) 2010-04-21
EA200300294A1 (ru) 2003-08-28
HK1056505A1 (en) 2004-02-20
CZ2003848A3 (cs) 2003-11-12
HRP20030102A2 (en) 2005-04-30
YU13603A (sh) 2006-05-25
GEP20063934B (en) 2006-10-10
DE60138892D1 (de) 2009-07-16
UA77945C2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
NO20030858L (no) Metode for behandling av en BCL-2-lidelse med BCL-2-antisens- oligomerer
NO20030241D0 (no) Fremgangsmåte for behandling av multiple brönnintervaller
NO20011121D0 (no) FremgangsmÕte for formasjonsbehandling med deformerbare partikler
ID30025A (id) Metode perlakuan tekstil
FI20000863L (fi) Uusi hoitomenetelmä
NO20011716D0 (no) Fremgangsmåte for behandling av petroleumsyrer med ammoniakk
PL342076A1 (en) Method of treating surfaces
DE60012333D1 (de) Strickware und strickverfahren
ZA200108494B (en) Method of treating cartilage damage.
GB0020847D0 (en) Method and device for treating textile articles
AU2003300414A8 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
PL349309A1 (en) Creatine fibre protecting composition, method of protecting creatine fibre and treatment set for chemically treating creatine fibre
NO20032789L (no) Apparat for lipolyse for estetisk behandling
FI19992513L (fi) Menetelmä ja laite rullanvaihdossa
GB2375780B (en) Apparatus and method for treating and gravel-packing closely spaced zones
GB2373205B (en) Method for treating ceramic cores
SE0101676D0 (sv) Method and apparatus for treating pulp
NO20031559L (no) Innretning og fremgangsmåte for behandling av spillvann med forbedret faststoffreduksjon
HUP0101995A3 (en) Method for treatment of aqueous streams comprising biosolids
GB0021481D0 (en) Method of treating fabric
DE69929003D1 (de) Garnbehandlungsdüse
EE200200705A (et) Süsteemid ja meetodid limaskesta ravimiseks
FI20001542L (fi) Menetelmä septisen sokin hoitamiseksi
IT1317173B1 (it) Macchina e procedimento per il trattamento di filati
GB0025728D0 (en) Method of handling loops of elasticated yarn